SEC Form 4 · accession 0001193125-26-349963
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Heidi L Wagner
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2026 | M | 7,000 | $5.97 | A | 51,930 | D | |
| Common Stock | Aug 11, 2026 | S | 7,000 | $6.01 | D | 44,930 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.97 | Aug 11, 2026 | M | 7,000 | D | — | Aug 16, 2026 | Ordinary Shares | 7,000 | 0 | D |
Explanation of responses
- F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
- F2These stock options are fully vested.
Remarks
On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney